Return to study ST003036 main page
MB Sample ID: SA328812
| Local Sample ID: | M_Cefto_3g_47h_F |
| Subject ID: | SU003150 |
| Subject Type: | Bacteria |
| Subject Species: | Pseudomonas aeruginosa |
| Taxonomy ID: | 287 |
| Genotype Strain: | CW41 |
| Age Or Age Range: | NA |
| Weight Or Weight Range: | NA |
| Gender: | Not applicable |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO003143 |
| Collection Summary: | A hypermutable P. aeruginosa clinical isolate, CW41, was challenged with ceftolozane-tazobactam (Zerbaxa®, MSD, Australia) in the HFIM (C3008-1 cartridges; FiberCell Systems Inc., Frederick, MD, USA), in five biological replicates performed across two studies. The first study, with replicates 1 and 2, was conducted over 167 h and the second study, with replicates 3, 4 and 5, over 215 h. Briefly, the studied isolate was characterized as susceptible to ceftolozane-tazobactam (MIC 4 mg/L), and MDR (i.e. resistant to at least 1 antibiotic from each of ≥3 antibiotic classes) (17-20). The HFIM studies used cation-adjusted Mueller Hinton broth (CAMHB) and agar (CAMHA) [Becton Dickinson & Co., Sparks, MD, USA, with 25.0 mg/L Ca2+ and 12.5 mg/L Mg2+]. Ceftolozane-tazobactam was administered to simulate steady-state concentrations of ceftolozane predicted to occur in the epithelial lining fluid of the lung in patients with CF, following daily doses of 3 g/1.5 g and 6 g/3 g via continuous infusion (10.6 and 21.3 mg/L, respectively) (21-23). Total bacterial populations were quantified on antibiotic-free CAMHA, and resistant subpopulations on CAMHA containing ceftolozane-tazobactam (12 and 20 mg/L). |
| Sample Type: | Bacterial cells |
